CombiMatrix Expands CustomArray Product Line with Introduction of CustomArray12K.NEWPORT BEACH Newport Beach, residential and resort city (1990 pop. 66,643), Orange co., S Calif., on Newport Bay and the Pacific Ocean; inc. 1906. It is a popular seaside resort and yachting center. Manufactures include electrical and medical equipment, computers, boats, and adhesives. , Calif. -- Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator ) announced today that its CombiMatrix group will launch the CustomArray(TM)12K DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. expression array, offering researchers the ability to order a fully customizable array with more than 12,000 sites. Researchers can place orders for CustomArray12K beginning in July by contacting CombiMatrix at 800-985-2269 or by accessing CombiMatrix's order site at www.customarray.com. CustomArray12K expands CombiMatrix's microarray portfolio to meet the needs of a broader research audience. CustomArray products enable researchers to study any combination of genes from any genome on a single chip. In addition to the complete customization and flexibility inherent in the CustomArray chips, CombiMatrix has simplified the ordering process with the first online custom microarray ordering website. "We're excited to introduce CustomArray12K which offers researchers a higher density CustomArray chip with the same superior performance seen with CustomArray902," said Jennifer Dent, Vice President of Business Development and Sales at CombiMatrix. "Customer feedback on CustomArray902 has been excellent and now with our higher density chip we can support more researchers with CustomArrays. At CombiMatrix our commitment is to exceed our customer's expectations by delivering the highest quality microarrays coupled with excellent customer service and support." CustomArray users benefit from many features including: --High performance standards and a commitment to customer satisfaction --Total customization of content on each CustomArray --Flexibility to study any genome, any gene, or any probe sequence --Delivery of custom microarrays within days --Convenient and easy online ordering --Flexible ordering of one or one thousand unique CustomArrays --Study of multiple genomes on the same CustomArray --No subscription or design fee --Standard microarray slide configuration --Image using commercially available scanners CustomArrays are semiconductor-based arrays (approx. 1 cm2) integrated onto a standard 1" x 3" slide format. CombiMatrix synthesizes oligonucleotides in situ In place. When something is "in situ," it is in its original location. to build CustomArrays. This revolutionary technology allows CombiMatrix to deliver CustomArrays in days. Sensitivity and performance metrics Performance metrics are measures of an organizations activities and performance. Performance metrics should support a range of stakeholder needs from customers, shareholders to employees [1]. are available on the company's main web site and at www.customarray.com. ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation comprises two operating groups: Acacia Technologies
The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand. CombiMatrix's Express Track(sm) drug discovery program is a systems biology Systems biology, a field of study in the biosciences, focuses on the systematic study of complex interactions in biological systems. Particularly from 2000 onwards, the term is used widely in the biosciences, and in a variety of contexts. approach, using its technology, to target common viral diseases viral diseases Diseases caused by viruses. Long-term immunity usually follows viral childhood diseases (see chickenpox). The common cold recurs into adulthood because many different viruses cause its symptoms, and immunity against one does not protect against others. with siRNA compounds. The Acacia Technologies Group develops, acquires, and licenses patented technologies. Acacia's DMT See DSL. technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems. Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. , recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion